Cheng-Hsun Chuang1,2,3,#, Ping-Kun Tsai3,4,5,6,#, Shih-Wen Kao7,8, Yu-Hsun Wang8,9,*, Chao-Bin Yeh1,2,3,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072875
- 30 December 2025
Abstract Background: To determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index (BMI). Methods: This retrospective cohort study used electronic health records from the TriNetX U.S. research network. Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis. Following 1:1 propensity score matching, both the GLP-1 RA user and non-user… More >
Graphic Abstract